2-(3-Fluoro-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 98.0%, 1g

(R)-2-((5-BROMO-2,3-DIFLUOROPHENOXY)METHYL)OXIRANE, 97.0%, 1g

4,6-Dichloro-5-fluoropyrimidin-2-amine, 95.0%, 250mg

Methyl 6-iodonicotinate, 95.0%, 25g

N-methyl-2-pyrrolidin-1-ylethanamine dihydrochloride, 95.0%, 1g

Ethyl 3-azabicyclo[3.1.0]hexane-1-carboxylate hydrochloride, 97.0%, 100mg

Vasos de muestra con cierre de rosca con área de graduación y etiquetado, 120 ml, No estéril, 500 Unidad(es)

(S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one, 97.0%, 10g

(S)-2-ALLYLPIPERIDINE HCL, 95%, 250mg

(Quinoxalin-2-ylthio)acetic acid, 97.0%, 1g

2-Maleimidoacetic Acid>98.0%(HPLC)(T)250mg

(4-((Trifluoromethyl)thio)phenyl)boronic acid, 95+%, 250mg

2-AMINO-4-CHLORO-6-PHENYL-1,3,5-TRIAZINE, 95.0%, 1g